Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up on Better-Than-Expected Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s share price gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $2.89, but opened at $3.30. Iovance Biotherapeutics shares last traded at $3.5510, with a volume of 23,411,626 shares traded.

The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. The business had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 55.24% and a negative net margin of 158.78%.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Positive clinical data — A pilot MSKCC trial of lifileucel in advanced soft-tissue sarcomas showed a 50% objective response rate, highlighting a meaningful addressable market (~8,000 U.S./EU patients annually) that could expand lifileucel’s commercial opportunity. Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
• Positive Sentiment: Quarterly beat — Iovance reported Q4 results with EPS of ($0.18) beating consensus (-$0.22) and revenue of $86.8M vs. $81.6M est., a sign of improving commercial traction and execution; management held a conference call. Iovance Q4 2025 earnings / transcript
• Positive Sentiment: Amtagvi data and analyst support — The company released new Amtagvi data that analysts describe as best-in-class for the product profile; H.C. Wainwright reiterated a Buy with a $9 target, supporting upside expectations. Iovance Shares New Amtagvi Data, Analysts Stay Positive
• Neutral Sentiment: Earnings/news flow ahead — Multiple previews and coverage note that Iovance’s upcoming/just-released results and continued Amtagvi adoption are catalysts to monitor; these items keep attention on near-term execution. Iovance earnings on deck as Amtagvi data spurs adoption hopes
• Neutral Sentiment: Analyst/comparison coverage — A Zacks comparison piece contrasts Iovance with Rigel (RIGL) on upside potential — useful context but not a direct catalyst. IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
• Negative Sentiment: Still unprofitable — Despite the beat, Iovance remains loss-making with negative ROE (~-55%) and deeply negative net margins (~-159%), and Wall Street still models continued negative EPS for the year; continued losses and cash burn are risk factors that could cap valuation.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IOVA shares. The Goldman Sachs Group reiterated a “sell” rating and set a $2.00 price objective on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. HC Wainwright lowered their price target on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Barclays increased their price target on Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Finally, Chardan Capital lowered their target price on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.50.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in IOVA. Vontobel Holding Ltd. acquired a new position in shares of Iovance Biotherapeutics in the third quarter worth approximately $26,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Iovance Biotherapeutics during the 3rd quarter worth approximately $27,000. Arcataur Capital Management LLC acquired a new position in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at $29,000. Finally, Motley Fool Asset Management LLC acquired a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth $29,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Up 31.0%

The business’s 50 day moving average is $2.61 and its two-hundred day moving average is $2.39. The firm has a market cap of $1.50 billion, a P/E ratio of -3.13 and a beta of 0.76.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.